Patient Registry
Research
We need your help.
Research Information
Research is the driving force behind the OHF’s mission, because research provides hope to the thousands of people worldwide living with the effects of hyperoxaluria. OHF-funded research has led to groundbreaking discoveries that have unlocked the secrets of primary hyperoxaluria—providing hope, energizing science, and helping save lives around the world. We encourage people with hyperoxaluria and their families to consider taking part in clinical research trials and the patient registry to help researchers unlock the secrets of hyperoxaluria, and bring us one step closer to a cure.
Patients who volunteer to participate in clinical trials make it possible for new drugs and therapies to be developed. By enrolling in a trial or signing up for a patient registry, you will help researchers unlock the secrets of hyperoxaluria, and bring us one step closer to a cure.
Clinical Trials 101
This is an exciting time in hyperoxaluria research. Not only are there several clinical trials studying therapies to treat the underlying cause of primary hyperoxaluria, many trials are also exploring ways to treat key symptoms of both primary and enteric (or secondary) hyperoxaluria and improve quality of life. If you are new to clinical research, this section will cover the basics of clinical trials. You will learn how your or your child's safety will be protected, why you might want to participate, and how to find a clinical trial.
Patients who volunteer to participate in observational studies and clinical research trials make it possible for new drugs and therapies to be developed. From observational studies to clinical trials, you can help researchers unlock the secrets of hyperoxaluria.
By participating in a clinical trial, you may benefit by:
- Gaining access to new treatments that are not yet available to the public
- Obtaining expert medical care at a leading healthcare facility
- Playing an active role in your own healthcare
- Helping others by contributing to medical research
When you or your child participate in a clinical trial, you will meet with doctors who will talk to you about what to expect. Doctors who are running the clinical trial have strict rules for how the treatments are given. This helps to keep you and your child safe. Before the trial begins, the doctors will discuss all risks with you, and they typically will perform certain tests to understand the health of you or your child.
Clinical trials often test experimental treatments. After you or your child have received these treatments for a certain period of time, the doctors will perform tests again. The results of these tests will be compared to the results from before the treatments are given. This helps doctors understand how effective and safe the treatments are.
Clinical trials are usually grouped into “phases,” which are stages of testing. Clinical trials in each phase are designed to answer certain questions, while trying to make sure the people taking part are kept as safe as possible. Every new treatment is tested in 3 or more phases of clinical trials before being considered reasonably safe and effective.
Read moreFor information on hyperoxaluria studies, go to ClinicalTrials.gov, a registry and results database of publicly and privately supported clinical studies conducted around the world.
Read moreAcademic Clinical Trials
An academic clinical trial is a clinical trial that is not funded by a pharmaceutical or biotechnology company for commercial ends, but by public-good agencies to advance medicine.
Enteric Hyperoxaluria
Title:
Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis
Location:
University Hospital Brussels, Brussels, Belgium
Contact:
Celine Olbrechts, Study Coordinator
- +32 (0)2 477 62 24
- Celine.Olbrechts@uzbrussel.be
Condition:
Hyperoxaluria
Title:
Prospective Research Rare Kidney Stones (ProRKS)
Location:
New York University, New York, New York, United States, University of Alabama at Birmingham, Birmingham, Alabama, United States
Contact:
Barb Seide
- 800-270-4637
- RareKidneyStones@mayo.edu Julie Olson, RN
- 800-270-4637
- RareKidneyStones@mayo.edu
Condition:
Primary Hyperoxaluria
Type:
Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric Patients
Location:
New York University School of Medicine, New York, New York, United States
Contact:
Lama Nazzal, MD
- 212-686-7500 ext 3877
- lama.nazzal@nyumc.org Jessica Baylor, BA
- 646-501-4159
- jessica.baylor@nyumc.org
Phases of a Clinical Trial
INITIAL RESEARCH
- Funded by OHF and other organizations looking for treatments for hyperoxaluria
PHASE I
- Evaluate safety
- Determine safe dosage
- Identify side effects
PHASE II
- Test effectiveness
- Further evaluate safety
PHASE III
- Confirm effectiveness
- Monitor side effects
- Compare to other treatments
- Collect information
FDA APPROVAL
- Treatment is approved and becomes widely available
PHASE IV
- Provide additional information after approval, including risks, benefits, and best use
Drug Development Pipeline
The Oxalosis & Hyperoxaluria Foundation facilitates the development of promising new drugs, and the drug development pipeline enables you to track the progress of these potential therapies.
Nearly every hyperoxaluria drug being investigated was made possible because of the OHF’s support and its ongoing work with researchers.
Patient Registry
How many people have primary hyperoxaluria? What kind of symptoms will I develop and when? How can I improve my health and keep my kidneys healthy?
These are very straightforward questions, but there is not sufficient information to accurately answer them at the moment. This is where you can make a big impact—your involvement can shape research and pave the way for new treatments.
Sign up today to learn more about the patient registry.
Grants and Funding
The Oxalosis & Hyperoxaluria Foundation disburses grants and funding to researchers who study the causes of hyperoxaluria and its treatment.
Research grants
Application deadline: December 15, 2019 at midnight ET
The OHF seeks to support research that will ultimately lead to new diagnostics, treatments, and a cure for primary hyperoxaluria and related hyperoxaluria conditions.
OHF will award up to $200,000 total cost per project after a competitive process to select the most meritorious projects.
Short-term travel grant
Application deadline: Open
The OHF’s short-term travel grant supports postdoctoral and mid-career researchers to receive hands-on training for up to 3 months in advanced host institutions or laboratories.
The ultimate goal is to improve the standards in each recipient’s home institution upon their return, which will help them become leaders in their fields.
Researchers receive hands-on training in outside laboratories, allowing them to acquire state-of-the-art knowledge of a new technique, methodology, or philosophical approach that would complement their own knowledge and experience and enhance their ability to carry out high-quality research compatible with the mission of the OHF.
OHF global registry initiative
Application deadline: Open
We are seeking proposals to develop international collaborative patient registries and databases to identify the determinants of the clinical manifestations and prognosis of patients with primary hyperoxaluria.
As part of its wider mission to improve the understanding and treatment of primary hyperoxaluria and related calcium oxalate kidney stone diseases, the Oxalosis & Hyperoxaluria Foundation is interested in receiving proposals from scientists and clinicians that address the issue of the influence of genetic, cultural, and environmental background on the clinical manifestations and prognosis of patients with primary hyperoxaluria. To this end, financial support will be given to international collaborative projects that develop and make use of well-defined patient cohorts covering a wide range of genetic and cultural backgrounds.
Possible questions to be addressed include, but are not limited to:
- The influence of urinary oxalate level and other urine parameters on renal outcomes.
- The influence of dietary intake on urinary oxalate level and renal outcomes.
- Genotype-phenotype correlations within and between primary hyperoxaluria types.
In countries where no such databases exist, the OHF is willing to provide funding to help local clinicians and scientists to organize collections of primary hyperoxaluria patient information into standardized registries and databases and to make this information available for approved research projects that address the issues above. A required element of a successful response to this proposal will be a detailed data-sharing plan for key data elements that are collected under this program.
Proposed timelines can be 1 to 2 years; however, additional funds will be available for registry maintenance to sites that achieve predefined benchmarks (eg, patient enrollment targets) in the first year. Successful proposals will benefit clinicians in treating primary hyperoxaluria patients and provide a framework for the evaluation of existing and potential new therapies.
Primary hyperoxaluria type 3 grant
Application deadline: Closed
Of the known genetic causes of primary hyperoxaluria, PH type 3 is the most recently identified and now known to be caused by mutations in the HOGA1 gene. Although the causative gene is known we still lack much basic information regarding this disease. Indeed, it is not entirely clear how mutations in this gene cause hyperoxaluria. It is not clear what the natural history is of this disorder or if there are treatment approaches that might be uniquely beneficial for PH3 over PH types 1 and 2.
To fill these gaps, the OHF specifically seeks funding applications to study PH type 3. Applications could be clinical, translational, or basic science in focus. Possible areas of study include, but are not limited to, the mechanism(s) of hyperoxaluria, novel treatment strategies and targets, novel biomarkers, and new information regarding risk factors for stone formation or chronic kidney disease in PH type 3.
OHF will award up to $200,000 total for up to 2 years. Indirect costs must be included in the maximum funding amount.